超声引导下腹外斜肌肋间平面阻滞与肋缘下腹横肌平面阻滞用于腹腔镜肝切除术后镇痛效果的比较

注册号:

Registration number:

ChiCTR2600121649 

最近更新日期:

Date of Last Refreshed on:

2026-04-01 15:07:52 

注册时间:

Date of Registration:

2026-04-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下腹外斜肌肋间平面阻滞与肋缘下腹横肌平面阻滞用于腹腔镜肝切除术后镇痛效果的比较

Public title:

Comparison of the analgesic effects of ultrasound-guided intercostal plane block of external oblique muscle and intercostal transverse muscle plane block of lower abdomen for laparoscopic liver resection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下腹外斜肌肋间平面阻滞与肋缘下腹横肌平面阻滞用于腹腔镜肝切除术后镇痛效果的比较

Scientific title:

Comparison of the analgesic effects of ultrasound-guided intercostal plane block of external oblique muscle and intercostal transverse muscle plane block of lower abdomen for laparoscopic liver resection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵阳熙 

研究负责人:

张毅 

Applicant:

Yangxi Zhao 

Study leader:

Yi Zhang 

申请注册联系人电话:

Applicant telephone:

+86 166 0555 9656

研究负责人电话:

Study leader's
telephone:

+86 139 8603 9131

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Yangxi-ZHao@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

yi_zhang18@tjh.tjmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市硚口区解放大道1095号

研究负责人通讯地址:

湖北省武汉市硚口区解放大道1095号

Applicant address:

No. 1095 Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

Study leader's address:

No. 1095 Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

华中科技大学同济医学院附属同济医院

Applicant's institution:

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

研究负责人所在单位:

华中科技大学同济医学院附属同济医院

Affiliation of the Leader:

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TJ-IRB202511013

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

华中科技大学同济医学院附属同济医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-11 00:00:00

伦理委员会联系人:

李娟

Contact Name of the ethic committee:

Juan Li

伦理委员会联系地址:

湖北省武汉市硚口区解放大道1095号

Contact Address of the ethic committee:

No. 1095 Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 8366 2379

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

华中科技大学同济医学院附属同济医院

Primary sponsor:

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

研究实施负责(组长)单位地址:

湖北省武汉市硚口区解放大道1095号

Primary sponsor's address:

No. 1095 Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院

具体地址:

湖北省武汉市硚口区解放大道1095号

Institution
hospital:

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Address:

No. 1095 Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

经费或物资来源:

武汉市知识创新专项项目(2022020801010444)

Source(s) of funding:

Wuhan Knowledge Innovation Special Project (2022020801010444)

研究疾病:

无  

Target disease:

None

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较腹外斜肌肋间平面阻滞与肋缘下腹横肌平面阻滞对腹腔镜肝切除术的患者的术后镇痛及恢复效果。  

Objectives of Study:

Compare the postoperative analgesic and recovery effects of intercostal plane block of external oblique muscle and intercostal transverse muscle plane block of lower abdomen on patients undergoing laparoscopic liver resection.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.日常使用阿片类镇痛药或者存在阿片类药物滥用史; 2.穿刺部位皮肤感染等无法进行神经阻滞的情况; 3.对研究中所用药物任一种过敏,或有过敏史; 4.存在认知功能障碍,有精神或神经系统疾病,存在运动或感觉缺陷,无法配合; 5.严重凝血功能障碍; 6.严重的肾、肝、肺或心功能障碍; 7.在入选研究前的3个月内参与了其他临床试验的。

Exclusion criteria:

1. Daily use of opioid analgesics or history of opioid abuse; 2. The situation where nerve block cannot be performed, such as skin infection at the puncture site; 3. Allergic to any of the drugs used in the study, or with a history of allergies; 4. Having cognitive impairment, mental or neurological disorders, motor or sensory deficits, and inability to cooperate; 5. Severe coagulation dysfunction; 6. Severe kidney, liver, lung, or heart dysfunction; 7. Participated in other clinical trials within the 3 months prior to enrollment in the study.

研究实施时间:

Study execute time:

From 2026-04-01 00:00:00 To 2027-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-01 00:00:00 To 2027-01-01 00:00:00

干预措施:

Interventions:

组别:

EOIB组

样本量:

42

Group:

EOIB group

Sample size:

干预措施:

在第6肋上,锁骨中线和腋前线间扫查进行双侧腹外斜肌肋间阻滞,每侧0.4%的罗哌卡因20 ml

干预措施代码:

Intervention:

Perform bilateral intercostal block of the external oblique muscles between the midline of the clavicle and the anterior axillary line on the 6th rib, with 20 ml of 0.4% ropivacaine on each side

Intervention code:

组别:

TAPB组

样本量:

42

Group:

TAPB group

Sample size:

干预措施:

接受超声引导下肋下腹横肌平面阻滞,在肋缘下进行阻滞,每侧20 ml 0.4%罗哌卡因

干预措施代码:

Intervention:

Undergoing ultrasound-guided transversus abdominis muscle plane block, performed below the rib margin, with 20 ml of 0.4% ropivacaine on each side

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三甲 

Institution
hospital:

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后24小时静息时累计曲线下面积视觉模拟评分AUC VAS

指标类型:

主要指标

Outcome:

Cumulative area under the curve at rest 24 hours after surgery Visual Analog Scale AUC VAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后1 h、 2 h、 4 h及8 h静息和咳嗽时AUC VAS

指标类型:

次要指标

Outcome:

AUC VAS at rest and cough at 1 h, 2 h, 4 h, and 8 h postoperatively

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后1 h、2 h、4 h、8 h、24 h静息和咳嗽时静息和咳嗽状态下VAS评分

指标类型:

次要指标

Outcome:

VAS scores at rest and cough state at 1 h, 2 h, 4 h, 8 h, and 24 h postoperatively

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后1 h、2 h、4 h、8 h及24 h补救性镇痛的次数、累积阿片类药物用量、不良反应

指标类型:

次要指标

Outcome:

The frequency of salvage analgesia, cumulative opioid dosage, and adverse reactions at 1 h, 2 h, 4 h, 8 h, and 24 h after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术前,术后1、3 d肝肾功能

指标类型:

次要指标

Outcome:

Preoperative and postoperative liver and kidney function on days 1 and 3

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术前,术后1 d中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值以及淋巴细胞/单核细胞比值等

指标类型:

次要指标

Outcome:

Preoperative and postoperative day 1 neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio, etc

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术前,术后1 d的QoR-15评分

指标类型:

次要指标

Outcome:

QoR-15 scores before and 1 day after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后腹腔引流管留置时间、住院时间等

指标类型:

次要指标

Outcome:

Postoperative retention time of abdominal drainage tube, length of hospital stay, etc

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

根据计算机生成的随机数字表将受试者按照1:1的比例随机分为2组:腹外斜肌肋间平面阻滞组(EOIB组)和肋下腹横肌平面阻滞组(TAPB组)。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to a computer-generated random number table, the subjects were randomly divided into two groups in a 1:1 ratio: the External Oblique Muscle intercostal plane block group (EOIB group) and the Transverse Muscle plane block group (TAPB group).

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对患者、负责数据收集和术后随访的麻醉医生设盲

Blinding:

Blinding for patients and anesthesiologists responsible for data collection and postoperative follow-up

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用纸质病例记录表 (Paper CRF) 进行原始数据采集。数据采集完成后,由双人独立录入至 Excel 数据库(或注明具体的统计软件)进行管理和核对。数据文件存储于受密码保护的专用计算机中,仅授权研究人员可访问。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study used a paper case record form (Paper CRF) for raw data collection. After the data collection is completed, it will be independently entered into an Excel database (or specified statistical software) by two people for management and verification. The data files are stored on a password protected dedicated computer and are only accessible to authorized researchers.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-01 15:07:46